SAN RAMON, Calif., Oct. 7 /PRNewswire/ -- Odyssey Thera, Inc. announced that it will receive milestone payments from one of its investors, Pfizer Inc. following Pfizer's decision to progress drug candidates studied by Odyssey Thera as part of Odyssey's multi-year alliance with Pfizer announced in August, 2006. These milestones are the Company's fourth and fifth to be earned for the advancement of specific drug candidates, and follow other technology development milestones previously achieved in the alliance.
"We are delighted to participate in the success of Pfizer's cutting-edge drug discovery programs," said John K. Westwick, Ph.D., Odyssey Thera's President and CEO. "We look forward to continued success in the application of our validated strategies, both in our partnerships and for our internal drug development programs."
About Odyssey Thera, Inc.
Odyssey Thera's patented technology measures disease-relevant pathway activity within living human cells. Odyssey is leveraging its proprietary drug discovery and development platform for internal programs and for premier pharmaceutical and biotechnology company partners.
To learn more about Odyssey Thera, please visit www.odysseythera.com.
SOURCE Odyssey Thera, Inc.
CONTACT: John Westwick of Odyssey Thera, Inc., +1-925-242-5011
Web site: http://www.odysseythera.com/